Lung preservation

Chest Surgery Clinics of North America

Volumn 13, Issue 3, 2003, Pages 443-462

  De Perrot, Marc ^a   Keshavjee, Shaf ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELSIOR; COMPLEMENT INHIBITOR; DEXTRAN; EURO COLLINS SOLUTION; LOW POTASSIUM DEXTRAN; NITRIC OXIDE; PERFADEX; PRESERVATION SOLUTION; PROSTAGLANDIN E1; RAFFINOSE; SURFACTANT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; UNIVERSITY OF WISCONSIN SOLUTION;

DNA MICROARRAY; GENETIC ANALYSIS; GRAFT DYSFUNCTION; GRAFT FAILURE; HEALTH CARE QUALITY; HOSPITAL ADMISSION; HUMAN; INCIDENCE; ISCHEMIA; LUNG DONOR; LUNG INJURY; LUNG STORAGE; LUNG TRANSPLANTATION; ORGAN DONOR; ORGAN PRESERVATION; OXYGENATION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SURGICAL TECHNIQUE; DONOR; GRAFT REJECTION; LUNG; LUNG DISEASE; METHODOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; VASCULARIZATION;

GRAFT REJECTION; HUMANS; LUNG; LUNG DISEASES; LUNG TRANSPLANTATION; ORGAN PRESERVATION; PATIENT SELECTION; REPERFUSION INJURY; TISSUE DONORS;

EID: 0041859695     PISSN: 10523359     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3359(03)00055-3     Document Type: Review

References (105)

1. Hertz M, Taylor D, Trulock E, Boucek M, Mohacsi P, Edwards L, et al. The registry of the international society for heart and lung transplantation: nineteenth official report - 2002. J Heart Lung Transplant 2002;21:950-70.
2. King RC, Binns OA, Rodriguez F, Kanithanon RC, Daniel TM, Spotnitz WD, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000;69:1681-5.
3. Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Jones DR, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002;73:1041-7.
4. Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant 1998; 17:423-9.
5. Sundaresan S, Trachiotis GD, Aoe M, Patterson GA, Cooper JD. Donor lung procurement: assessment and operative technique. Ann Thorac Surg 1993;56:1409-13.
6. Sundaresan S, Semenkovich J, Ochoa L, Richardson G, Trulock EP, Cooper JD, et al. Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. J Thorac Cardiovasc Surg 1995;109:1075-9.
7. Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000;19:1199-204.
8. Gabbay E, Williams TJ, Griffiths AP, Macfarlane LM, Kotsimbos TC, Esmore DS, et al. Maximizing the utilization of donor organs offered for lung transplantation. Am J Respir Crit Care Med 1999;160:265-71.
9. Pierre AF, Sekine Y, Hutcheon MA, Waddell TK, Keshavjee SH. Marginal donor lungs: a reassessment. J Thorac Cardiovasc Surg 2002;123:421-8.
10. Fisher AJ, Donnelly SC, Hirani N, Haslett C, Strieter RM, Dark JH, et al. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med 2001;163:259-65.
11. de Perrot M, Sekine Y, Fischer S, Waddell TK, McRae K, Liu M, et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 2002;165:211-5.
12. Hopkinson DN, Bhabra MS, Hooper TL. Pulmonary graft preservation: a worldwide survey of current clinical practice. J Heart Lung Transplant 1998;17:525-31.
13. Fujimura S, Handa M, Kondo T, Ichinose T, Shiraishi Y, Nakada T. Successful 48-hour simple hypothermic preservation of canine lung transplants. Transplant Proc 1987;19:1334-6.
14. Keshavjee SH, Yamazaki F, Cardoso PF, McRitchie DI, Patterson GA, Cooper JD. A method for safe twelve-hour pulmonary preservation. J Thorac Cardiovasc Surg 1989;98:529-34.
15. Date H, Matsumura A, Manchester JK, Obo H, Lima O, Cooper JM, et al. Evaluation of lung metabolism during successful twenty-four-hour canine lung preservation. J Thorac Cardiovasc Surg 1993;105:480-91.
16. Keshavjee SH, Yamazaki F, Yokomise H, Cardoso PF, Mullen JB, Slutsky AS, et al. The role of dextran 40 and potassium in extended hypothermic lung preservation for transplantation. J Thorac Cardiovasc Surg 1992;103:314-25.
17. Al Mehdi AB, Zhao G, Dodia C, Tozawa K, Costa K, Muzykantov V, et al. Endothelial NADPH oxidase as the source of oxidants in lungs exposed to ischemia or high K+. Circ Res 1998;83:730-7.
18. Sasaki S, McCully JD, Alessandrini F, LoCicero III J. Impact of initial flush potassium concentration on the adequacy of lung preservation. J Thorac Cardiovasc Surg 1995;109:1090-5.
19. Spaggiari L, Bobbio P. Dextran 40 at 2% versus 5% in low-potassium solutions: which is best? Ann Thorac Surg 1994;58:1784-6.
20. Schneuwly OD, Licker M, Pastor CM, Schweizer A, Slosman DO, Kapanci Y, et al. Beneficial effects of leukocyte-depleted blood and low-potassium dextran solutions on microvascular permeability in preserved porcine lung. Am J Respir Crit Care Med 1999;160:689-97.
21. Sakamaki F, Hoffmann H, Munzing S, Krombach F, Messmer K, Schildberg FW. Effects of lung preservation solutions on PMN activation in vitro. Transpl Int 1999;12:113-21.
22. Maccherini M, Keshavjee SH, Slutsky AS, Patterson GA, Edelson JD. The effect of lowpotassium-dextran versus Euro-Collins solution for preservation of isolated type II pneumocytes. Transplantation 1991;52:621-6.
23. Suzuki S, Inoue K, Sugita M, Tsubochi H, Kondo T, Fujimura S. Effects of EP4 solution and LPD solution vs Euro-Collins solution on Na(+)/K(+)-ATPase activity in rat alveolar type II cells and human alveolar epithelial cell line A549 cells. J Heart Lung Transplant 2000;19:887-93.
24. Sakamaki F, Hoffmann H, Muller C, Dienemann H, Messmer K, Schildberg FW. Reduced lipid peroxidation and ischemia-reperfusion injury after lung transplantation using low-potassium Dextran solution for lung preservation. Am J Respir Crit Care Med 1997;156:1073-81.
25. Struber M, Hohlfeld JM, Fraund S, Kim P, Warnecke G, Haverich A. Low-potassium Dextran solution ameliorates reperfusion injury of the lung and protects surfactant function. J Thorac Cardiovasc Surg 2000;120:566-72.
26. Hopkinson DN, Odom NJ, Bridgewater BJ, Hooper TL. Comparison of saccharides as osmotic impermeants during hypothermic lung graft preservation. Transplantation 1996;61: 1667-71.
27. Hopkinson DN, Odom NJ, Bridgewater BJ, Hooper TL. University of Wisconsin solution for lung graft preservation: which components are important? J Heart Lung Transplant 1994; 13:990-7.
28. Fischer S, Hopkinson D, Liu M, Keshavjee S. Raffinose improves the function of rat pulmonary grafts stored for twenty-four hours in low-potassium Dextran solution. J Thorac Cardiovasc Surg 2000;119:488-92.
29. Fischer S, Hopkinson D, Liu M, Maclean AA, Edwards V, Cutz E, et al. Raffinose improves 24-hour lung preservation in low potassium Dextran glucose solution: a histologic and ultrastructural analysis. Ann Thorac Surg 2001;71:1140-5.
30. Fischer S, Matte-Martyn A, de Perrot M, Waddell TK, Sekine Y, Hutcheon M, et al. Low-potassium Dextran preservation solution improves lung function after human lung transplantation. J Thorac Cardiovasc Surg 2001;121:594-6.
31. Struber M, Wilhelmi M, Harringer W. Niedermeyer J, Anssar M, Kunsebeck A, et al. Flush perfusion with low potassium Dextran solution improves early graft function in clinical lung transplantation. Eur J Cardiothorac Surg 2001;19:190-4.
32. Muller C, Furst H, Reichenspumer H, Briegel J, Groh J, Reichart B. Lung procurement by low-potassium Dextran and the effect on preservation injury. Munich Lung Transplant Group. Transplantation 1999;68:1139-43.
33. Thabut G, Vinatier I, Brugiere O, Leseche G, Loirat P, Bisson A, et al. Influence of preservation solution on early graft failure in clinical lung transplantation. Am J Respir Crit Care Med 2001; 164:1204-8.
34. Haverich A, Aziz S, Scott WC, Jamieson SW, Shumway NE. Improved lung preservation using Euro-Collins solution for flush-perfusion. Thorac Cardiovasc Surg 1986;34:368-76.
35. Steen S, Sjoberg T, Massa G, Ericsson L, Lindberg L. Safe pulmonary preservation for 12 hours with low-potassium-dextran solution. Ann Thorac Surg 1993;55:434-40.
36. Steen S, Kimblad PO, Sjoberg T, Lindberg L, Ingemansson R, Massa G. Safe lung preservation for twenty-four hours with Perfadex. Ann Thorac Surg 1994;57:450-7.
37. Sasaki M, Muraoka R, Chiba Y, Hiramatu Y. Influence of pulmonary arterial pressure during flushing on lung preservation. Transplantation 1996;61:22-7.
38. Tanaka H, Chiba Y, Sasaki M, Matsukawa S, Muraoka R. Relationship between flushing pressure and nitric oxide production in preserved lungs. Transplantation 1998;65:460-4.
39. Andrade RS, Wangensteen OD, Jo JK, Tsai MY, Bolman III RM. Effect of hypothermic pulmonary artery flushing on capillary filtration coefficient. Transplantation 2000;70:267-71.
40. Kimblad PO, Massa G, Sjoberg T, Steen S. Endothelium-dependent relaxation in pulmonary arteries after lung preservation and transplantation. Ann Thorac Surg 1993;56:1329-33.
41. Wang LS, Nakamoto K, Hsieh CM, Miyoshi S, Cooper JD. Influence of temperature of flushing solution on lung preservation. Ann Thorac Surg 1993;55:711-5.
42. Albes JM, Fischer F, Bando T, Heinemann MK, Scheule A, Wahlers T. Influence of the perfusate temperature on lung preservation: is there an optimum? Eur Surg Res 1997;29:5-11.
43. Fehrenbach H, Riemann D, Wahlers T, Hirt SW, Haverich A, Richter J. Scanning and transmission electron microscopy of human donor lungs: fine structure of the pulmonary parenchyma following preservation and ischemia. Acta Anat (Basel) 1994;151:220-31.
44. Muller C, Hoffmann H, Bittmann I, Isselhard W, Messmer K, Dienemann H, et al. Hypothermic storage alone in lung preservation for transplantation: a metabolic, light microscopic, and functional analysis after 18 hours of preservation. Transplantation 1997;63:625-30.
45. The Toronto Lung Transplant Group. Experience with single-lung transplantation for pulmonary fibrosis. JAMA 1988;259:2258-62.
46. Steen S, Sjoberg T, Ingemansson R, Lindberg L. Efficacy of topical cooling in lung preservation: is a reappraisal due? Ann Thorac Surg 1994;58:1657-63.
47. Haverich A, Scott WC, Jamieson SW. Twenty years of lung preservation - a review. J Heart Transplant 1985;4:234-40.
48. Date H, Matsumura A, Manchester JK, Cooper JM, Lowry OH, Cooper JD. Changes in alveolar oxygen and carbon dioxide concentration and oxygen consumption during lung preservation. The maintenance of aerobic metabolism during lung preservation. J Thorac Cardiovasc Surg 1993;105:492-501.
49. Fukuse T, Hirata T, Nakamura T, Kawashima M, Hitomi S, Wada H. Influence of deflated and anaerobic conditions during cold storage on rat lungs. Am J Respir Crit Care Med 1999;160: 621-7.
50. DeCampos KN, Keshavjee S, Liu M, Slutsky AS. Optimal inflation volume for hypothermic preservation of rat lungs. J Heart Lung Transplant 1998;17:599-607.
51. Sakuma T, Tsukano C, Ishigaki M, Nambu Y, Osanai K, Toga H, et al. Lung deflation impairs alveolar epithelial fluid transport in ischemic rabbit and rat lungs. Transplantation 2000;69: 1785-93.
52. Baretti R, Bitu-Moreno J, Beyersdorf F, Matheis G, Francischetti I, Kreitmayr B. Distribution of lung preservation solutions in parenchyma and airways: influence of atelectasis and route of delivery. J Heart Lung Transplant 1995;14:80-91.
53. Haniuda M, Hasegawa S, Shiraishi T, Dresler CM, Cooper JD, Patterson GA. Effects of inflation volume during lung preservation on pulmonary capillary permeability. J Thorac Cardiovasc Surg 1996;112:85-93.
54. Aoe M, Okabayashi K, Cooper JD, Patterson GA. Hyperinflation of canine lung allografts during storage increases reperfusion pulmonary edema. J Thorac Cardiovasc Surg 1996;112: 94-102.
55. Kayano K, Toda K, Naka Y, Pinsky DJ. Identification of optimal conditions for lung graft storage with Euro-Collins solution by use of a rat orthotopic lung transplant model. Circulation 1999;100:II257-61.
56. Fukuse T, Hirata T, Ishikawa S, Shoji T, Yoshimura T, Chen Q, et al. Optimal alveolar concentration for cold storage of the lung. Transplantation 2001;72:300-4.
57. Date H, Lima O, Matsumura A, Tsuji H, d'Avignon DA, Cooper JD. In a canine model, lung preservation at 10 degrees C is superior to that at 4 degrees C. A comparison of two preservation temperatures on lung function and on adenosine triphosphate level measured by phosphorus 31-nuclear magnetic resonance. J Thorac Cardiovasc Surg 1992;103:773-80.
58. Kirk AJ, Colquhoun IW, Dark JH. Lung preservation: a review of current practice and future directions. Ann Thorac Surg 1993;56:990-1000.
59. Sarsam MA, Yonan NA, Deiraniya AK, Rahman AN. Retrograde pulmonaryplegia for lung preservation in clinical transplantation: a new technique. J Heart Lung Transplant 1993;12: 494-8.
60. Varela A, Montero C, Cordoba M, Serrano-Fiz S, Burgos R, Tellez JC, et al. Clinical experience with retrograde lung preservation. Transpl Int 1996;9(Suppl 1):S296-8.
61. Struber M, Hohlfeld JM, Kofidis T, Warnecke G, Niedermeyer J, Sommer SP, et al. Surfactant function in lung transplantation after 24 hours of ischemia: advantage of retrograde flush perfusion for preservation. J Thorac Cardiovasc Surg 2002;123:98-103.
62. Chen CZ, Gallagher RC, Ardery P, Dyckman W, Donabue S, Low HB. Retrograde flush and cold storage for twenty-two to twenty-five hours lung preservation with and without prostaglandin E1. J Heart Lung Transplant 1997;16:658-66.
63. Varela A, Cordoba M, Serrano-Fiz S, Burgos R, Montero CG, Tellez G, et al. Early lung allograft function after retrograde and antegrade preservation. J Thorac Cardiovasc Surg 1997;114:1119-20.
64. Venuta F, Rendina EA, Bufi M, Della RG, De Giacomo T, Costa MG, et al. Preimplantation retrograde pneumoplegia in clinical lung transplantation. J Thorac Cardiovasc Surg 1999;118: 107-14.
65. Serrick CJ, Jamjoum A, Reis A, Giaid A, Shennib H. Amelioration of pulmonary allograft injury by administering a second rinse solution. J Thorac Cardiovasc Surg 1996;112:1010-6.
66. Gao WS, Takei Y, Marzi I, Lindert KA, Caldwell-Kenkel JC, Currin RT, et al. Carolina rinse solution - a new strategy to increase survival time after orthotopic liver transplantation in the rat. Transplantation 1991;52:417-24.
67. Pierre AF, DeCampos KN, Liu M, Edwards V, Cutz E, Slutsky AS, et al. Rapid reperfusion causes stress failure in ischemic rat lungs. J Thorac Cardiovasc Surg 1998;116:932-42.
68. Bhabra MS, Hopkinson DN, Shaw TE, Onwu N, Hooper TL. Controlled reperfusion protects lung grafts during a transient early increase in permeability. Ann Thorac Surg 1998;65:187-92.
69. de Perrot M, Imai Y, Ranieri VM, Waddell TK, Liu M, McRae K, et al. Impact of ventilator induced lung injury on the development of reperfusion injury in a rat lung transplant model. J Thorac Cardiovasc Surg 2002;124:1137-44.
70. McRae KM. Pulmonary transplantation. Curr Opin Anesthesiol 2000;13:53-9.
71. Marczin N, Riedel B, Gal J, Polak J, Yacoub M. Exhaled nitric oxide during lung transplantation. Lancet 1997;350:1681-2.
72. Pinsky DJ, Naka Y, Chowdhury NC, Liao H, Oz MC, Michler RE, et al. The nitric oxide/cyclic GMP pathway in organ transplantation: critical role in successful lung preservation. Proc Natl Acad Sci USA 1994;91:12086-90.
73. Vainikka T, Heikkila L, Kukkonen L, Toivonen HJ. L-arginine in lung graft preservation and reperfusion. J Heart Lung Transplant 2001;20:559-67.
74. Sandera P, Hillinger S, Stammberger U, Schoedon G, Zalunardo M, Weder W, et al. 8-Br-cyclic GMP given during reperfusion improves post-transplant lung edema and free radical injury. J Heart Lung Transplant 2000;19:173-8.
75. Murakami S, Bacha EA, Mazmanian GM, Detruit H, Chapelier A, Dartevelle P, et al. Effects of various timings and concentrations of inhaled nitric oxide in lung ischemia-reperfusion. The Paris-Sud University Lung Transplantation Group. Am J Respir Crit Care Med 1997;156:454-8.
76. Kawashima M, Bando T, Nakamura T, Isowa N, Liu M, Toyokuni S, et al. Cytoprotective effects of nitroglycerin in ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2000;161:935-43.
77. Schmid RA, Hillinger S, Walter R, Zollinger A, Stammberger U, Speich R, et al. The nitric oxide synthase cofactor tetrahydrobiopterin reduces allograft ischemia-reperfusion injury after lung transplantation. J Thorac Cardiovasc Surg 1999;118:726-32.
78. Fehrenbach A, Wittwer T, Meyer D, von Vietinghoff S, Viehover M, Fehrenbach H, et al. Nitroglycerin alters alveolar type II cell ultrastructure after ischemia and reperfusion. J Heart Lung Transplant 2001;20:876-88.
79. Bhabra MS, Hopkinson DN, Shaw TE, Hooper TL. Modulation of lung reperfusion injury by nitric oxide: impact of inspired oxygen fraction. Transplantation 1999;68:1238-43.
80. Adatia I, Lillehei C, Arnold JH, Thompson JE, Palazzo R, Fackler JC, et al. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994;7:1311-8.
81. Date H, Triantafillou AN, Trulock EP, Pohl MS, Cooper JD, Patterson GA. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996;111:913-9.
82. Ardehali A, Laks H, Levine M, Shpiner R, Ross D, Watson LD, et al. A prospective trial of inhaled nitric oxide in clinical lung transplantation. Transplantation 2001;72:112-5.
83. Thabut G, Brugiere O, Leseche G, Stern JB, Fradj K, Herve P, et al. Preventive effect of inhaled nitric oxide and pentoxifylline on ischemia/reperfusion injury after lung transplantation. Transplantation 2001;71:1295-300.
84. Meade M, Granton JT, Matte-Martyn A, McRae K, Cripps PM, Weaver B, et al. A randomized trial of inhaled nitric oxide to prevent reperfusion injury following lung transplantation [abstract]. J Heart Lung Transplant 2001;20:254-5.
85. de Perrot M, Fischer S, Liu M, Jin R, Bai XH, Waddell TK, et al. Prostaglandin El protects lung transplants from ischemia-reperfusion injury: a shift from pro- to anti-inflammatory cytokines. Transplantation 2001:72:1505-12.
86. Aoe M, Trachiotis GD, Okabayashi K, Manchester JK, Lowry OH, Cooper JD, et al. Administration of prostaglandin E1 after lung transplantation improves early graft function. Ann Thorac Surg 1994;58:655-61.
87. DeCampos KN, Keshavjee S, Liu M, Slutsky AS. Prevention of rapid reperfusion-induced lung injury with prostaglandin E1 during the initial period of reperfusion. J Heart Lung Transplant 1998;17:1121-8.
88. Matsuzaki Y, Waddell TK, Puskas JD, Hirai T, Nakajima S, Slutsky AS, et al. Amelioration of post-ischemic lung reperfusion injury by prostaglandin E1. Am Rev Respir Dis 1993;148:882-9.
89. Himmelreich G, Hundt K, Neuhaus P, Bechstein WO, Roissant R, Riess H. Evidence that intraoperative prostaglandin E1 infusion reduces impaired platelet aggregation after reperfusion in orthotopic liver transplantation. Transplantation 1993;55:819-26.
90. Christie JD, Bavaria JE, Palevsky HI, Litzky L, Blumenthal NP, Kaiser LR, et al. Primary graft failure following lung transplantation. Chest 1998;114:51-60.
91. Lockinger A, Schutte H, Walmrath D, Seeger W, Grimminger F. Protection against gas exchange abnormalities by pre-aerosolized PGE1, iloprost and nitroprusside in lung ischemia-reperfusion. Transplantation 2001;71:185-93.
92. Ivey CL, Williams FM, Collins PD, Jose PJ, Williams TJ. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8. J Clin Invest 1995;95:2720-8.
93. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000;105:1363-71.
94. Pierre AF, Xavier AM, Liu M, Cassivi SD, Lindsay TF, Marsh HC, et al. Effect of complement inhibition with soluble complement receptor I on pig allotransplant lung function. Transplantation 1998;66:723-32.
95. Schmid RA, Zollinger A, Singer T, Hillinger S, Leon-Wyss JR, Schob OM, et al. Effect of soluble complement receptor type 1 on reperfusion edema and neutrophil migration after lung allotransplantation in swine. J Thorac Cardiovasc Surg 1998;116:90-7.
96. Keshavjee SH, Davis RD, Zamora MR, Schulman L, Levin J, Ryan U, et al. Inhibition of complement in human lung transplant reperfusion injury: a multicenter clinical trial [abstract]. J Heart Lung Transplant 1998;13:254.
97. Zamora MR, Davis RD, Keshavjee SH, Schulman L, Levin J, Ryan U, et al. Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest 1999;116:46S.
98. Rioux P. TP-10 (AVANT Immunotherapeutics). Curr Opin Investig Drugs 2001;2:364-71.
99. Corcoran PC, Wang Y, Katz NM, Rajan SS, Analouei AR, Foegh ML, et al. Platelet activating factor antagonist enhances lung preservation in a canine model of single lung allotransplantation. J Thorac Cardiovasc Surg 1992;104:66-72.
100. Kawahara K, Tagawa T, Takahashi T, Akamine S, Nakamura A, Yamamoto S, et al. The effect of the platelet-activating factor inhibitor TCV-309 on reperfusion injury in a canine model of ischemic lung. Transplantation 1993;55:1438-9.
101. Wittwer T, Grote M, Oppelt P, Franke U, Schaefers HJ, Wahlers T. Impact of PAF antagonist BN 52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation. J Heart Lung Transplant 2001;20:358-63.
102. Novick RJ, MacDonald J, Veldhuizen RA, Wan F, Duplan J, Denning L, et al. Evaluation of surfactant treatment strategies after prolonged graft storage in lung transplantation. Am J Respir Crit Care Med 1996;154:98-104.
103. Struber M, Hirt SW. Cremer J, Harringer W. Haverich A. Surfactant replacement in reperfusion injury after clinical lung transplantation. Intensive Care Med 1999;25:862-4.
104. Warnecke G, Struber M, Fraud S, Hohlfeld JM, Haverich A. Combined exogenous surfactant and inhaled nitric oxide therapy for lung ischemia-reperfusion injury in minipigs. Transplantation 2001;71:1238-44.
105. Della Rocca G, Pierconti F, Costa MG, Coccia C, Pompei L, Rocco M, et al. Severe reperfusion injury after double lung transplantation. Crit Care 2002;6:240-4.